4582SymBio Pharmaceuticals4582 info
$1.74info2.48%24h
Global rank23440
Market cap$71.26M
Change 7d-8.49%
YTD Performance0.00%
SP500 benchmarkUnderperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    SymBio Pharmaceuticals (4582) Stock Overview

    SymBio Pharmaceuticals Limited engages in the research and development, manufacturing, and marketing of pharmaceutical drugs and other related activities in the areas of oncology and hematology in Japan and internationally. It offers SyB L-0501, an anti-cancer agent, which is marketed for the treatment of non-Hodgkin's lymphoma, multiple myeloma, chronic lymphocytic leukemia, and relapsed/refractory diffuse large B-cell lymphoma; SyB L-1701, a ready-to-dilute formulation; and SyB L-1702, a rapid infusion liquid administrator under the TREAKISYM name. The company also engages in the development of SyB L-1101, an intravenous formulation, which completed Phase III clinical trial for the treatment of higher-risk myelodysplastic syndromes (HR-MDS); and SyB C-1101, an oral formulation that is in Phase I/II clinical trial in combination with AZA to treat HR-MDS. In addition, it is involved in the development SyB V-1901, an antiviral drug. SymBio Pharmaceuticals Limited was incorporated in 2005 and is based in Tokyo, Japan.

    4582 Stock Information

    Symbol
    4582
    Address
    Toranomon 30 Mori BuildingTokyo, 105-0001Japan
    Founded
    -
    Trading hours
    -
    Website
    https://www.symbiopharma.com
    Country
    🇯🇵 Japan
    Phone Number
    81 3 5472 1125

    SymBio Pharmaceuticals (4582) Price Chart

    -
    Value:-

    SymBio Pharmaceuticals Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $1.74
    N/A
    Market Cap
    $71.26M
    N/A
    Shares Outstanding
    40.99M
    N/A
    Employees
    122.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    © 2024 Topstocks.org